



Title	Aberrant functional connectivity between anterior cingulate cortex and left insula in association with therapeutic response to biologics in inflammatory arthritis
Author(s)	Abe, Nobuya; Fujieda, Yuichiro; Tha, Khin K.; Narita, Hisashi; Aso, Kuniyuki; Karino, Kohei; Kanda, Masatoshi; Kono, Michihito; Kato, Masaru; Amengual, Olga; Atsumi, Tatsuya
Citation	Seminars in arthritis and rheumatism, 55, 151994 <a href="https://doi.org/10.1016/j.semarthrit.2022.151994">https://doi.org/10.1016/j.semarthrit.2022.151994</a>
Issue Date	2022-08
Doc URL	<a href="http://hdl.handle.net/2115/90291">http://hdl.handle.net/2115/90291</a>
Rights	© 2022. This manuscript version is made available under the CC-BY-NC-ND 4.0 license <a href="https://creativecommons.org/licenses/by-nc-nd/4.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</a>
Rights(URL)	<a href="https://creativecommons.org/licenses/by-nc-nd/4.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</a>
Type	article (author version)
Additional Information	There are other files related to this item in HUSCAP. Check the above URL.
File Information	SAR 55 151994.pdf



[Instructions for use](#)

1 **Title: Aberrant functional connectivity between anterior cingulate cortex and**  
2 **left insula in association with therapeutic response to biologics in**  
3 **inflammatory arthritis**

4  
5 **Authors:** Nobuya Abe, MD, PhD<sup>1</sup>, Yuichiro Fujieda, MD, PhD<sup>1\*</sup>, Khin K. Tha, MD, PhD<sup>2,3</sup>,  
6 Hisashi Narita, MD, PhD<sup>4</sup>, Kuniyuki Aso, MD<sup>1</sup>, Kohei Karino, MD, PhD<sup>1</sup>, Masatoshi Kanda,  
7 MD, PhD<sup>1,5</sup>, Michihito Kono, MD, PhD<sup>1</sup>, Masaru Kato, MD, PhD<sup>1</sup>, Olga Amengual, MD, PhD<sup>1</sup>,  
8 Tatsuya Atsumi, MD, PhD<sup>1</sup>

9  
10 **Affiliations:** <sup>1</sup>Department of Rheumatology, Endocrinology and Nephrology, Faculty of  
11 Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.

12 <sup>2</sup>Department of Diagnostic and Interventional Radiology, Hokkaido University Hospital,  
13 Sapporo, Japan.

14 <sup>3</sup>Global Center for Biomedical Science and Engineering, Faculty of Medicine, Hokkaido  
15 University, Sapporo, Japan.

16 <sup>4</sup>Department of Psychiatry, Faculty of Medicine, Hokkaido University, Sapporo, Japan.

17 <sup>5</sup>Department of Rheumatology and Clinical Immunology, School of Medicine, Sapporo Medical  
18 University, Sapporo, Japan.

19  
20 **\*Corresponding author:** Yuichiro Fujieda

21 Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido  
22 University, Kita 15, Nishi 7, Kita-ku, Sapporo, 0608648, Japan.

23 Email: edaichi@med.hokudai.ac.jp; Telephone number: +81117065915; Fax: +81117067710

24  
25 **Declarations of interest:** none

26 **Word count:** 3139

28 **ABSTRACT**

29 **Background:** Brain activity is reported to be associated with individual pain susceptibility and  
30 inflammatory status, possibly contributing to disease activity assessment in inflammatory  
31 arthritis (IA) including rheumatoid arthritis (RA) and spondyloarthritis (SpA). However, what  
32 alteration of brain function associated with disease activity and therapeutic effectiveness in IA  
33 remains unclear. We aimed to identify the alterations of brain functional connectivity (FC)  
34 shared in both RA and SpA, and evaluate its relationship to anti-rheumatic treatment response  
35 using functional magnetic resonance imaging (MRI).

36 **Patients and methods:** Structural and resting-state functional MRI data were acquired from  
37 patients with IA, patients with osteoarthritis (OA) and healthy controls (HCs). Two datasets were  
38 adopted to derive (51 IA, 56 OA, and 17 HCs) and validate (31 IA) the observations. Thirty-  
39 three IA patients in the derivation dataset and all the patients in validation dataset required  
40 biological treatment and were clinically evaluated before and after therapy. Via whole-brain pair-  
41 wise FC analyses, we analyzed IA-specific FC measures relevant to therapeutic response to  
42 biologics.

43 **Results:** The value of FC between left insular cortex (IC) and anterior cingulate cortex (ACC)  
44 was significantly low in IA patients compared with OA patients and HCs. We demonstrated that  
45 the FC between left anterior long insular gyrus as a subdivision of IC and ACC was significantly  
46 associated with therapeutic response to biologics regarding the improvement of patients' global  
47 assessment (PGA) in both derivation and validation datasets.

48 **Conclusion:** Disease-specific resting-state FC provides a means to assess the therapeutic  
49 improvement of PGA and would be a clinical decision-making tool with predictability for  
50 treatment response in both RA and SpA.

51 **Keywords:** resting-state functional magnetic resonance imaging; neuroimaging; rheumatoid  
52 arthritis; spondyloarthritis; functional connectivity; patient reported outcome  
53

54 **INTRODUCTION**

55 The brain is a central organ controlling neurotransmission, and also plays an essential role in  
56 vital actions as perception, motor coordination, cognition, emotion, and reasoning [1-4].  
57 Furthermore, it interacts with autonomic activity to maintain homeostasis via the neuroendocrine  
58 system, covering immune control [5, 6]. Although many researches demonstrate that these  
59 neurobiological regulations are relevant to the development of various neuropsychiatric and  
60 neurodegenerative disorders [7], those remain to be fully elucidated in systemic autoimmune  
61 diseases [6, 8]. Inflammatory arthritis (IA) such as rheumatoid arthritis (RA) and  
62 spondyloarthritis (SpA) is a representative autoimmune disease characterized by progressive and  
63 irreversible bone deformity caused by autoimmune joint inflammation despite anti-rheumatic  
64 treatment. Especially in IA, the brain function would affect the patients' pain perception and  
65 systemic inflammation status [8-12]. Direct neuronal interaction with joint inflammation and  
66 pain response was previously demonstrated in the mouse model of arthritis [13, 14]. In humans,  
67 the studies using functional magnetic resonance imaging (fMRI) demonstrated neural cross-  
68 sectional correlations with serological inflammation and pain centralization of IA patients [9, 11,  
69 12]. On the other hand, chronic pain and systemic inflammation themselves affects brain  
70 function. The observation about chronic pain-induced alteration of brain function, called central  
71 sensitization as pain hypersensitivity, is reported in both patients with autoimmune IA [9, 10],  
72 and osteoarthritis (OA) which demonstrates non-inflammatory mechanical pain in multiple joints  
73 [15, 16]. Also, it is reported that systemic inflammation affects functional alteration of some  
74 brain areas such as medial frontal cortex and inferior parietal lobule, and robustly causes  
75 cognitive dysfunction and mood disorders [11, 17, 18]. Considering these concepts, we wonder  
76 that disease activity assessment including patients' reported outcomes (e.g. patients' global  
77 assessment (PGA) for self-assessed disease status) and systemic inflammation state, and  
78 therapeutic response to anti-rheumatic drugs would be affected by brain function in patients with  
79 IA. For the development of appropriate medical care from neurological aspects in IA, we thus

80 aimed to explore the common therapeutic response-related functional alteration of the brain  
81 among RA and SpA patients, using resting-state fMRI.

82

## 83 **PATIENTS and METHODS**

### 84 **Participants**

85 Data of patients with IA were collected from a derivation cohort of 51 patients and a validation  
86 cohort of 31 patients scanned at Hokkaido University Hospital, Sapporo, Japan. IA includes RA  
87 and SpA. The patients with RA and SpA met 2010 American College of Rheumatology (ACR)  
88 RA classification criteria [19], and the Assessment of SpondyloArthritis international Society  
89 (ASAS) classification criteria for axial or peripheral SpA [20, 21], respectively. Among IA  
90 patients in the derivation dataset, 33 patients required therapeutic intention by biological disease  
91 modifying anti-rheumatic drugs and had clinical data before and after therapy. All the 31 IA  
92 patients in the validation dataset needed biologics treatment and were clinically evaluated before  
93 and after therapy. In the validation dataset, the IA patients were scanned twice: before therapy  
94 and 3 months after therapy. Data of 17 healthy controls (HCs) were also acquired at Hokkaido  
95 University. Inclusion criteria for healthy controls were >18 years old and free of psychiatric and  
96 neurological history. Data of 56 patients with OA were acquired from OpenNeuro, an open  
97 platform for sharing neuroimaging datasets (doi: 10.18112/openneuro.ds000208.v1.0.0) [22].  
98 Data of OA patients and those of HCs were used as a disease control with non-inflammatory pain  
99 and a control without any pain, respectively. The study was approved by the Institutional Review  
100 Board of Hokkaido University Hospital (reference number: 010-0031, 018-0128 and 018-0222).  
101 The present study complies with the Declaration of Helsinki. We obtained informed consent for  
102 the study and publication from all the patients included in this study.

103

### 104 **Clinical assessment for the patients with IA**

105 Clinical assessments for RA include followings: simplified disease activity index (SDAI)  
106 calculated by tender and swollen joint count (TJC/SJC), PGA/evaluator's global assessment

107 (EGA) for disease status, and serum level of C-reactive protein (CRP) [23]; and Disease Activity  
108 Score 28 (DAS28)-CRP calculated by TJC, SJC, PGA, and serum CRP level [24]. Twenty-eight  
109 joints for TJC and SJC includes shoulders, elbows, knees, wrists, and each finger and thumb  
110 (metacarpophalangeal or proximal interphalangeal joints). PGA and EGA are evaluated by a  
111 visual analogue scale scored from 0 to 10. Clinical evaluations for SpA include followings: the  
112 Ankylosing Spondylitis Disease Activity Score (ASDAS)-CRP calculated by back pain,  
113 peripheral pain/swelling, morning stiffness duration, PGA, and serum level of CRP [25]; the  
114 Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) calculated by fatigue, back pain,  
115 joint pain/swelling, enthesitis, and morning stiffness and duration [26]; and the Bath Ankylosing  
116 Spondylitis Functional Index (BASFI) consisted of ten questions about physical function [27].  
117 Therapeutic response is defined as at least 20% improvement in ACR core set of disease activity  
118 measures for clinical trials in RA [28], and ASAS20 improvement in SpA [29]. The IA patients  
119 in both datasets were functionally assessed by following questionnaires: the modified Health  
120 Assessment Questionnaire (mHAQ) for patients' functional status in activities of daily living  
121 (range: 0-3.0) [30]; EuroQol 5 dimensions 5 level (EQ5D-5L) for measuring generic health  
122 status (maximum value: 1.0) [31]; and Revised Fibromyalgia Impact Questionnaire (FIQR).  
123 FIQR consists of the 3 domains regarding (i) function for daily living (nine items), (ii) overall  
124 impact for accomplishing goals and overwhelming (two items), and (iii) symptoms such as pain,  
125 fatigue and mental (10 items) graded on a 0-10 numeric scale in each item [32].

126

### 127 **Imaging acquisition parameters**

128 All brain imaging data were acquired on a 3.0 T MRI scanner (Achieva TX, Philips Medical  
129 Systems) and a standard 32-channel radio frequency head coil (Philips Medical Systems, Best,  
130 the Netherlands). T2\*-weighted images were acquired using an echo-planar imaging sequence,  
131 which took approximately 7 minutes in duration, with the following parameters: repetition time  
132 (TR) 3,000 ms, echo time (TE) 30 ms, flip angle 80°, field of view 24 cm × 24 cm, matrix size  
133 64 × 64, slice thickness 3.3 mm, interslice gap 3.3 mm, 48 axial slices, and 140 volumes. During

134 scanning, the patient was instructed to rest calmly with her eyes open and not to sleep. The  
135 patient also did not undergo any cognitive task during the scan. The structural T1 magnetization-  
136 prepared rapid gradient echo images of the head were acquired with the following parameters:  
137 TR 7 ms, TE 3 ms, flip angle 8°, field of view 24 cm × 24 cm, matrix size 256 × 256, slice  
138 thickness 1.2 mm, interslice gap 1.2 mm, and 170 sagittal slices.

139

#### 140 **Data preprocessing and denoising, and brain atlas**

141 Preprocessing was performed using Statistical Parametric Mapping 12 software (SPM12;  
142 Wellcome Department of Cognitive Neurology, London, UK) and the CONN toolbox  
143 ([www.nitrc.org/projects/conn](http://www.nitrc.org/projects/conn)) implemented in MATLAB (Mathworks, Natick, MA, USA) [33].  
144 Default preprocessing pipeline included motion correction, realignment, slice-timing correction,  
145 outlier identification, coregistration to structural scan, segmentation, normalization to Montreal  
146 Neurological Institute space, and spatial smoothing (8 mm Gaussian kernel). Structural scans  
147 were skull stripped and segmented into grey matter, white matter and cerebrospinal fluid (CSF)  
148 masks using the unified segmentation approach implemented in Statistical Parametric Mapping  
149 12. For functional data, the four initial volumes were discarded to allow for stabilization of the  
150 magnetic field. Motion artifact detection was performed with the artifact detection toolbox (ART  
151 toolbox). Outliers' images were subsequently included as nuisance regressors within the first-  
152 level general liner model (GLM) to remove any influence of these outlier scans on time series.  
153 For physiological and other sources of noise decrement, the noise was estimated and regressed  
154 out using CompCor, a component-based noise correction method [34]: the effect of noise was  
155 modelled as a voxel specific linear combination of multiple estimated noise sources by  
156 calculating principal components from noise regions and by adding them as parameters within  
157 the GLMs. The white matter and CSF masks were used as noise regions of interest (ROIs) and  
158 removed with regression. A temporal band-pass filter of 0.008 to 0.09 Hz was applied to the time  
159 series for removing high-frequency activity related to the cardiac and respiratory activity.

160 Residual blood oxygen level-dependent (BOLD) time series were yielded to be extracted for  
161 subsequent analysis by these corrections.

162 A total of 132 atlas-based ROIs from FSL Harvard-Oxford Atlas maximum likelihood cortical  
163 and subcortical atlas, and AAL atlas for cerebellum were selected [35, 36]. For a detailed  
164 analysis of insula, probabilistic atlases of insular subregion were used to subdivide insular cortex  
165 (IC) into six subregions: anterior IC consisting of anterior pole, anterior short gyrus, middle short  
166 gyrus and posterior short gyrus, and posterior IC consisting of anterior long gyrus and posterior  
167 long gyrus (Supplementary Table S1) [37].

168

### 169 **Functional connectivity analysis**

170 ROI-to-ROI analyses were performed to compute Pearson's bivariate correlation coefficients  
171 between a pair of ROIs BOLD time series among each subject [38]. As standardized within the  
172 CONN toolbox, correlations underwent a Fisher's Z-transformation. In first-level analysis, static  
173 functional connectivity was calculated using the entire BOLD time series of each subject. For  
174 second-level analyses, group level contrasts included age, sex, and disease. The ROI-based  
175 inferences method was applied to control false positives. First, a different cluster of connections  
176 for each row of the ROI-to-ROI matrix was defined to group all connections which arose from  
177 the same ROI as a new cluster. Second, we then performed a multivariate parametric GLM for  
178 all connections included in each of these new clusters of connections, deriving an F-statistic for  
179 each ROI and a related uncorrected ROI-level p-value. Using the Benjamini-Hochberg method, a  
180 false discovery rate (FDR)-corrected ROI-level p-value is generated as the expected proportion  
181 of false discoveries among all ROIs with effects across the entire set of ROIs. The top 10%  
182 correlations between ROIs within the absolute value of functional connectivity  $> 0.2$  are  
183 rendered on the axial anatomical brain view generated by BrainNet Viewer software [39].

184



## 185 **Statistical analysis**

186 We used ANCOVA adjusting age and sex as confounds to compare the values of continuous  
187 variables. For multiple comparisons among groups, Bonferroni method was used to generate  
188 family-wise-error (FWE)-corrected p-value. Pearson product-moment correlation coefficient was  
189 calculated for a linear correlation between clinical parameters and fMRI data measures. A  
190 receiver operating characteristic (ROC) analysis was performed to evaluate the accuracy for  
191 treatment response corresponding to functional connectivity value with the area under the curve  
192 (AUC). We used JMP Pro 14 (SAS Institute Inc., Cary, NC, USA) for all analyses. The analysis  
193 results were considered to demonstrate statistical significance when the p-value was below 0.05.  
194 All statistical tests were two-sided.

## 196 **Data statement**

197 Participants' whole-brain correlation matrices and the clinical data are available upon a  
198 reasonable request to the corresponding author.

## 200 **RESULTS**

### 201 **Resting-state functional connectivity with disease-specificity for inflammatory arthritis**

202 To study neuronal correlates regarding disease activity in patients with IA, we first evaluated  
203 disease-specific resting-state functional correlations among each brain area and compared them  
204 with those of HCs and OA patients (Fig. 1A, Supplementary Tables S2 and S3). We assessed the  
205 difference of brain functional coordination among the groups in the derivation dataset. We  
206 detected 1283 differentially correlated functional connectivity with statistical significance among  
207 the groups (Fig. 1B, Supplementary Fig. S1A and B, Supplementary Table S1). Among these  
208 regions, we detected the altered functional coupling with left insular cortex (IC) and anterior  
209 cingulate cortex (ACC) as only statistically significant connectivity in the IA patients compared  
210 to the HCs and OA patients (Fig. 1C). The functional connectivity between these areas showed  
211 the lowest value in the patients with IA (Fig. 1D).

212 To achieve a detailed understanding of the functional coordination, we considered anatomical  
213 subdivisions of IC into six parts: anterior pole, anterior/middle/posterior short gyrus and  
214 anterior/posterior long gyrus (Fig. 2A, Supplementary Table S1) [40]. We calculated functional  
215 connectivity between ACC and subdivided areas in left IC, and found the almost significant  
216 connections to anterior pole and anterior long insular gyrus (IG) with the lowest functional  
217 connectivity value in IA (Fig. 2B).

218

### 219 **Therapeutic response to biologics predicted by resting-state functional connectivity**

220 We next assessed therapeutic effectiveness with biological anti-rheumatic drugs by comparing  
221 the functional connectivity between ACC and left whole IC, anterior pole, or anterior long IG. In  
222 the derivation dataset including 33 patients with IA who required therapy intensification using  
223 biologics and had clinical data before and after therapy, there were no differences of the baseline  
224 characteristics between treatment-effective and -ineffective group (Supplementary Table S4).  
225 Functional connectivity value between left anterior long IG and ACC was significantly higher in  
226 the treatment-effective group than -ineffective group (Fig. 3A), but functional connectivity value  
227 between ACC and whole left IC or left anterior pole were similar between the treatment-effective  
228 group and -ineffective group (Supplementary Fig. S2A and B). Furthermore, the functional  
229 correlation of ACC and left anterior long IG had a significant accuracy for treatment  
230 effectiveness with the AUC 0.7269 (95% confidence interval 0.5394-0.9145) in ROC analysis  
231 (Fig. 3B). For validation, we applied these results to the 31 IA patients with similar baseline  
232 characteristics in the validation dataset (Supplementary Table S5). As with the results from the  
233 derivation dataset, the IA patients with therapeutic response had significantly higher functional  
234 connectivity between left anterior long IG and ACC before treatment than those with therapeutic  
235 resistance (Fig. 3C), and the functional correlation between left anterior long IG and ACC before  
236 treatment consistently had the best accuracy for treatment response with AUC 0.8070 (0.6561-  
237 0.9579) of ROC analysis in the validation dataset (Fig. 3D).

238

239 **Improvement of patient reported outcomes correlated with resting-state functional**  
240 **connectivity**

241 We finally focused on the transition of functional connectivity value between left anterior long  
242 IG and ACC by biological anti-rheumatic treatment, and the improvement of clinical parameters  
243 from the aspect of baseline functional connectivity using whole dataset. We found that functional  
244 connectivity among whole brain regions were self-correlated (Supplementary Fig. S3A), and that  
245 the functional coordination values between left anterior long IG and ACC did not vary after the  
246 3-month treatment condition (Fig. 4).

247 In contrast, the baseline functional connectivity between left anterior long IG and ACC was  
248 significantly correlated with therapeutic improvement of disease activity score assessed by SDAI  
249 for RA and ASDAS-CRP for SpA (Fig. 5A). Similarly, DAS28-CRP for RA and BASDAI for  
250 SpA were correlated with the baseline functional connectivity (Fig. 5B). The connectivity also  
251 had significant correlation with patients' reported outcomes as PGA of the disease and FIQR for  
252 chronic pain assessment (Fig. 5C and D). Among FIQR domains, the domain 1 for daily living  
253 function and domain 3 for physical and mental symptoms including pain sensation especially had  
254 strong correlation with the functional connectivity (Supplementary Fig. S3B-D). In addition, the  
255 functional connectivity had significant correlations with after-treatment clinical parameters,  
256 including PGA, EGA, TJC, disease activity indices for RA, and indicators for physical function,  
257 pain perception, and quality of life (Supplementary Table S6). Thus, functional connectivity  
258 between ACC and left anterior long IG, which is a subdivided part of IC, was significantly  
259 associated with therapeutic response including disease activity and patients' reported outcomes  
260 in IA patients.

261

262 **DISCUSSION**

263 In this study, we focused on left IC and ACC as the brain regions specific for IA patients with  
264 low functional connectivity value compared to OA patients and HC. We also demonstrated  
265 functional connectivity between ACC and left anterior long IG, a subdivision of IC, significantly

266 affected therapeutic response to biological anti-rheumatic treatment regarding the improvements  
267 of disease activity, especially PGA in the patients with RA and SpA.

268 How does the functional connectivity between left IC and ACC affect clinical assessment in IA?  
269 These brain regions play a role of individual susceptibility to the influence of pain and  
270 inflammation [9, 11, 41]. IC and ACC are also known as limbic regions dealing with  
271 interoception, the sensation of the physiological condition of the entire body, to estimate and  
272 balance the autonomic, metabolic, and immunological assets [42-45]. Considering subparts of  
273 IC, anterior long IG in posterior IC has a distinct role in interoceptive prediction as primary  
274 interoceptive viscerosensory cortex from anterior IC and ACC as visceromotor cortices. Granular  
275 cortices like anterior long IG with well-defined layer IV incoming sensory input from the  
276 thalamus could transmit prediction error to agranular visceromotor regions to modify predictions,  
277 regarded as active interoceptive inference for maintaining homeostasis or enabling allostasis  
278 [42]. Our study revealed that IA patients especially with ineffective therapeutic response to  
279 biologics had dissociative functional connections between left IC and ACC regions, which might  
280 suggest interoceptive ineptness via inappropriate anticipatory responses to facing situations in  
281 agranular cortices and unregulated noisy afferent interoceptive inputs in granular cortices.

282 Therefore, patients with low functional connectivity between ACC and left anterior long IG  
283 would acquire lower satisfaction as a lack of PGA improvement than those with high  
284 connectivity despite appropriate anti-rheumatic treatment demonstrated by sufficient reduction of  
285 systemic inflammation levels. According to the value of the functional connectivity between left  
286 anterior long IG and ACC, the difference of local inflammation in the joints should be explored  
287 between IA patients with or without therapeutic response in further analysis.

288 The sustained aversive neural pain signals correlated with the clinical course of diseases [46].  
289 Although both chronic pain and peripheral inflammation contribute to structural and functional  
290 changes in pain-processing brain regions in the context of pain centralization [9, 11],  
291 corticolimbic connection relevant to motivation-valuation circuitry is revealed to be a top-  
292 controlling predictor for pain persistence. In this study, we evaluated the functional connectivity

293 of inflammatory chronic pain from IA patients, non-inflammatory chronic pain from OA patients  
294 and pain-free status from HCs. In addition, the functional connectivity value between left IC and  
295 ACC that we identified was not associated with the disease duration of IA. Therefore, it would  
296 be much subjected to the presence of systemic inflammation, and thus would be a robust  
297 neurobiological marker predicting therapeutic effectiveness from the viewpoint of PGA  
298 improvement shared in both RA and SpA patients.

299 We acknowledge several limitations in this study: first, this is a single-center retrospective study.  
300 Although a multicenter study is required for a definitive conclusion, our study could validate the  
301 results, strengthening its credibility; second, we used the dataset of HCs including relatively  
302 young people compared with others and those of OA patients from USA. The difference of age  
303 and race is not negligible for the neuroimaging analysis. However, our result of the IA-specific  
304 functional connectivity was derived from adjusting age effects in GLM and comparing the IA  
305 patients with other two datasets. Therefore, we could find the functional connectivity between  
306 left IC and ACC as the robust characteristic of IA; third, cause-and-effect relationship between  
307 the altered functional connectivity and disease activity status in IA was not provided by our  
308 study. Future basic studies in rodents or interventional research in humans are needed to  
309 establish the detailed neural association including neurological pathway and its mechanism for  
310 disease pathogenesis in IA.

311 Our data suggest that brain functional connectivity is aberrant in systemic autoimmune  
312 inflammatory disorders including RA and SpA. An important matter for future studies may be  
313 what neurological pathway is associated and how the circuitry modifies the assessment of  
314 individual status. Nonetheless, our present study would give an epochal insight that brain  
315 communication is associated with clinical characteristics to some extent, possibly involving  
316 clinical decision-making in therapeutic strategy.

317

318 **ACKNOWLEDGMENTS**

319 We thank Ms. Naomi Tamura from Centre for Environmental and Health Sciences, Hokkaido  
320 University, for the advice of statistical analysis. We thank BioRender.com for the creation of  
321 figures.

322

323 **AUTHOR CONTRIBUTIONS**

324 **Nobuya Abe:** Conceptualization, Methodology, Software, Formal analysis, Writing – original  
325 draft. **Yuichiro Fujieda:** Conceptualization, Investigation, Writing – original draft,  
326 Visualization. **Khin K. Tha and Hisashi Narita:** Methodology, Software, Resources. **Kuniyuki**  
327 **Aso, Kohei Karino, Michihito Kono, Masaru Kato, Olga Amengual:** Resources. **Masatoshi**  
328 **Kanda:** Software. **Tatsuya Atsumi:** Writing – review & editing, Supervision.

329

330 **FUNDING SOURCES**

331 This research did not receive any specific grant from funding agencies in the public, commercial,  
332 or not-for-profit sectors.

333

334 **REFERENCES**

335 1 Romo R, Rossi-Pool R. Turning Touch into Perception. *Neuron* 2020;105:16-33.

336 2 Rizzolatti G, Sinigaglia C. The mirror mechanism: a basic principle of brain function.  
337 *Nat. Rev. Neurosci.* 2016;17:757-65.

338 3 Bressler SL, Menon V. Large-scale brain networks in cognition: emerging methods and  
339 principles. *Trends Cogn. Sci.* 2010;14:277-90.

340 4 Damasio A, Carvalho GB. The nature of feelings: evolutionary and neurobiological  
341 origins. *Nat. Rev. Neurosci.* 2013;14:143-52.

342 5 Ulrich-Lai YM, Herman JP. Neural regulation of endocrine and autonomic stress  
343 responses. *Nat. Rev. Neurosci.* 2009;10:397-409.

344 6 Dantzer R. Neuroimmune Interactions: From the Brain to the Immune System and Vice  
345 Versa. *Physiol. Rev.* 2018;98:477-504.

346 7 Henry JD, von Hippel W, Molenberghs P, Lee T, Sachdev PS. Clinical assessment of  
347 social cognitive function in neurological disorders. *Nat. Rev. Neurol.* 2016;12:28-39.

348 8 Chavan SS, Pavlov VA, Tracey KJ. Mechanisms and Therapeutic Relevance of Neuro-  
349 immune Communication. *Immunity* 2017;46:927-42.

350 9 Basu N, Kaplan CM, Ichesco E, et al. Neurobiologic Features of Fibromyalgia Are Also  
351 Present Among Rheumatoid Arthritis Patients. *Arthritis Rheumatol.* 2018;70:1000-7.

352 10 Bidad K, Gracey E, Hemington KS, Mapplebeck JCS, Davis KD, Inman RD. Pain in  
353 ankylosing spondylitis: a neuro-immune collaboration. *Nat. Rev. Rheumatol.* 2017;13:410-20.

354 11 Schrepf A, Kaplan CM, Ichesco E, et al. A multi-modal MRI study of the central  
355 response to inflammation in rheumatoid arthritis. *Nat. Commun.* 2018;9:2243.

356 12 Hemington KS, Wu Q, Kucyi A, Inman RD, Davis KD. Abnormal cross-network  
357 functional connectivity in chronic pain and its association with clinical symptoms. *Brain Struct.*  
358 *Funct.* 2016;221:4203-19.

359 13 Hess A, Axmann R, Rech J, et al. Blockade of TNF- $\alpha$  rapidly inhibits pain responses in  
360 the central nervous system. *Proc. Natl. Acad. Sci. U. S. A.* 2011;108:3731-6.

361 14 Bassi GS, Dias DPM, Franchin M, et al. Modulation of experimental arthritis by vagal  
362 sensory and central brain stimulation. *Brain. Behav. Immun.* 2017;64:330-43.

363 15 O'Leary H, Smart KM, Moloney NA, Blake C, Doody CM. Pain sensitization associated  
364 with nonresponse after physiotherapy in people with knee osteoarthritis. *Pain* 2018;159:1877-86.

365 16 Pujol J, Martínez-Vilavella G, Llorente-Onaindia J, et al. Brain imaging of pain  
366 sensitization in patients with knee osteoarthritis. *Pain* 2017;158:1831-8.

367 17 Eisenberger NI, Inagaki TK, Rameson LT, Mashal NM, Irwin MR. An fMRI study of  
368 cytokine-induced depressed mood and social pain: the role of sex differences. *Neuroimage*  
369 2009;47:881-90.

370 18 Wallin K, Solomon A, K reholt I, Tuomilehto J, Soininen H, Kivipelto M. Midlife  
371 rheumatoid arthritis increases the risk of cognitive impairment two decades later: a population-  
372 based study. *J. Alzheimers Dis.* 2012;31:669-76.

373 19 Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an  
374 American College of Rheumatology/European League Against Rheumatism collaborative  
375 initiative. *Ann. Rheum. Dis.* 2010;69:1580-8.

376 20 Rudwaleit M, Landew  R, van der Heijde D, et al. The development of Assessment of  
377 SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I):  
378 classification of paper patients by expert opinion including uncertainty appraisal. *Ann. Rheum.*  
379 *Dis.* 2009;68:770-6.

380 21 Rudwaleit M, van der Heijde D, Landew  R, et al. The Assessment of SpondyloArthritis  
381 International Society classification criteria for peripheral spondyloarthritis and for  
382 spondyloarthritis in general. *Ann. Rheum. Dis.* 2011;70:25-31.

383 22 T treault P, Mansour A, Vachon-Preseau E, Schnitzer TJ, Apkarian AV, Baliki MN.  
384 Brain Connectivity Predicts Placebo Response across Chronic Pain Clinical Trials. *PLoS Biol.*  
385 2016;14:e1002570.

386 23 Smolen JS, Breedveld FC, Schiff MH, et al. A simplified disease activity index for  
387 rheumatoid arthritis for use in clinical practice. *Rheumatology (Oxford)* 2003;42:244-57.

388 24 Wells G, Becker JC, Teng J, et al. Validation of the 28-joint Disease Activity Score  
389 (DAS28) and European League Against Rheumatism response criteria based on C-reactive  
390 protein against disease progression in patients with rheumatoid arthritis, and comparison with the  
391 DAS28 based on erythrocyte sedimentation rate. *Ann. Rheum. Dis.* 2009;68:954-60.

392 25 Lukas C, Landew  R, Sieper J, et al. Development of an ASAS-endorsed disease activity  
393 score (ASDAS) in patients with ankylosing spondylitis. *Ann. Rheum. Dis.* 2009;68:18-24.

394 26 Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach  
395 to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease  
396 Activity Index. *J. Rheumatol.* 1994;21:2286-91.



397 27 Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in  
398 ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. *J.*  
399 *Rheumatol.* 1994;21:2281-5.

400 28 Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology  
401 preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The  
402 Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. *Arthritis Rheum.*  
403 1993;36:729-40.

404 29 Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing  
405 spondylitis assessment group preliminary definition of short-term improvement in ankylosing  
406 spondylitis. *Arthritis Rheum.* 2001;44:1876-86.

407 30 Pincus T, Summey JA, Soraci SA, Jr., Wallston KA, Hummon NP. Assessment of patient  
408 satisfaction in activities of daily living using a modified Stanford Health Assessment  
409 Questionnaire. *Arthritis Rheum.* 1983;26:1346-53.

410 31 Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new  
411 five-level version of EQ-5D (EQ-5D-5L). *Qual. Life Res.* 2011;20:1727-36.

412 32 Bennett RM, Friend R, Jones KD, Ward R, Han BK, Ross RL. The Revised Fibromyalgia  
413 Impact Questionnaire (FIQR): validation and psychometric properties. *Arthritis Res. Ther.*  
414 2009;11:R120.

415 33 Whitfield-Gabrieli S, Nieto-Castanon A. Conn: a functional connectivity toolbox for  
416 correlated and anticorrelated brain networks. *Brain Connect.* 2012;2:125-41.

417 34 Behzadi Y, Restom K, Liao J, Liu TT. A component based noise correction method  
418 (CompCor) for BOLD and perfusion based fMRI. *Neuroimage* 2007;37:90-101.

419 35 Desikan RS, Ségonne F, Fischl B, et al. An automated labeling system for subdividing  
420 the human cerebral cortex on MRI scans into gyral based regions of interest. *Neuroimage*  
421 2006;31:968-80.

422 36 Tzourio-Mazoyer N, Landeau B, Papathanassiou D, et al. Automated anatomical labeling  
423 of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-  
424 subject brain. *Neuroimage* 2002;15:273-89.

425 37 Faillenot I, Heckemann RA, Frot M, Hammers A. Macroanatomy and 3D probabilistic  
426 atlas of the human insula. *Neuroimage* 2017;150:88-98.

427 38 Smith SM, Vidaurre D, Beckmann CF, et al. Functional connectomics from resting-state  
428 fMRI. *Trends Cogn. Sci.* 2013;17:666-82.

429 39 Xia M, Wang J, He Y. BrainNet Viewer: a network visualization tool for human brain  
430 connectomics. *PLoS One* 2013;8:e68910.

431 40 Benarroch EE. Insular cortex: Functional complexity and clinical correlations. *Neurology*  
432 2019;93:932-8.

433 41 Labrenz F, Wrede K, Forsting M, et al. Alterations in functional connectivity of resting  
434 state networks during experimental endotoxemia - An exploratory study in healthy men. *Brain.*  
435 *Behav. Immun.* 2016;54:17-26.

436 42 Barrett LF, Simmons WK. Interoceptive predictions in the brain. *Nat. Rev. Neurosci.*  
437 2015;16:419-29.

438 43 Craig AD. How do you feel? Interoception: the sense of the physiological condition of  
439 the body. *Nat. Rev. Neurosci.* 2002;3:655-66.

440 44 Critchley HD, Wiens S, Rotshtein P, Ohman A, Dolan RJ. Neural systems supporting  
441 interoceptive awareness. *Nat. Neurosci.* 2004;7:189-95.

442 45 Khalsa SS, Rudrauf D, Feinstein JS, Tranel D. The pathways of interoceptive awareness.  
443 *Nat. Neurosci.* 2009;12:1494-6.

444 46 Baliki MN, Petre B, Torbey S, et al. Corticostriatal functional connectivity predicts  
445 transition to chronic back pain. *Nat. Neurosci.* 2012;15:1117-9.

446

447 **FIGURE LEGENDS**

448 **Figure 1. Exploration of specific functional connectivity in inflammatory arthritis**

449 (A) Experimental protocol for resting-state functional magnetic resonance imaging (MRI). (B)  
450 Statistically significant connectivity matrix 132 brain regions of interest (ROIs) across subjects  
451 in the derivation dataset including patients with inflammatory arthritis (IA,  $n = 51$ ) and  
452 osteoarthritis (OA,  $n = 56$ ) and healthy controls (HCs,  $n = 17$ ). Lines with statistical significance  
453 via ANCOVA adjusting age and sex with false-discovery-rate correction among all ROIs with  
454 effects across the entire set of ROIs using Benjamini-Hochberg method, are color-coded by F-  
455 statics. (C) Reference brain images of left insular cortex (IC) (red) and anterior cingulate cortex  
456 (ACC) (blue) (left panel). Intersection of reference lines indicates centroids of the coordinates of  
457 ROIs. Time-series Blood-oxygen-level-dependent (BOLD) signals of the subject groups (right  
458 panel). Data are average (solid line)  $\pm$  s.e.m. (band). (D) Group level multiple comparison in the  
459 values of functional connectivity between left IC and ACC. Data are mean  $\pm$  s.e.m.  $**P_{\text{Family-Wise-}}$   
460  $\text{Error (FWE)} < 0.01$ ,  $***P_{\text{FWE}} < 0.001$ , ANCOVA adjusting age and sex with Bonferroni method.

461

462 **Figure 2. Detailed functional connectivity analysis for subdivisions of left insular cortex**  
463 **and anterior cingulate cortex**

464 (A) Six subdivisions of left insular cortex. (B) Group level multiple comparison of functional  
465 connection values between subdivided regions in left insular cortex and anterior cingulate cortex  
466 among IA and OA patients and HCs.  $*P_{\text{Family-Wise-Error}} < 0.05$ , ANCOVA adjusting age and sex  
467 with Bonferroni method.

468

469 **Figure 3. Accuracy of the functional connectivity for therapeutic response in IA**

470 (A) Functional connectivity (FC) value between left anterior long insular gyrus (IG) and anterior  
471 cingulate cortex according to therapeutic effectiveness among IA patients in the derivation  
472 dataset ( $n = 33$ ). (B) Receiver operating curve (ROC) analysis for treatment effectiveness using  
473 FC between left anterior long IG and ACC in the derivation dataset. (C) FC value between left

474 anterior long IG and ACC corresponding to therapeutic effectiveness in the validation dataset ( $n$   
475 = 31 per groups). **(D)** ROC analysis for treatment effectiveness using FC between left anterior  
476 long IG and ACC in the validation dataset. Data are mean  $\pm$  s.e.m, \* $P < 0.05$ , \*\* $P < 0.01$ ,  
477 ANCOVA adjusting age and sex with general liner model.

478

479 **Figure 4. Stable baseline value of functional connectivity despite treatment**

480 Constancy of functional connectivity value between left anterior long insular gyrus and anterior  
481 cingulate gyrus before and after treatment in the patients with inflammatory arthritis of the  
482 validation dataset ( $n = 31$ ).

483

484 **Figure 5. The correlations of functional connectivity with clinical parameters**

485 **(A-D)** Correlation analysis using Pearson's correlation coefficient between functional  
486 connectivity (FC) of interest and the improvement of clinical parameters, which is adjusted by  
487 age and sex: **(A)** disease activity score SDAI and ASDAS-CRP, **(B)** disease activity score  
488 DAS28-CRP and BASDAI, **(C)** patients' global assessment, and **(D)** Fibromyalgia Impact  
489 Questionnaire (FIQR) in whole dataset.


490

491 **GRAPHICAL ABSTRACT**


492 Functional connectivity between anterior cingulate cortex and left anterior long insular gyrus,  
493 which is a subdivided part of insular cortex, demonstrated a significant accuracy for therapeutic  
494 response including disease activity and patients' reported outcomes in patients with  
495 inflammatory arthritis.

496


497







**A** Left insular cortex (IC)



**B** Functional connectivity between subdivided left IC and ACC











IA ( $n = 31$ )  
in validation dataset

Functional connectivity between  
left long anterior IG and ACC



**A****B****C****D**